Kintara Therapeutics, Inc. (NASDAQ:KTRA) Expected to Announce Earnings of -$0.15 Per Share

Analysts expect Kintara Therapeutics, Inc. (NASDAQ:KTRAGet Rating) to post ($0.15) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Kintara Therapeutics’ earnings. Kintara Therapeutics reported earnings of ($0.23) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 34.8%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Kintara Therapeutics will report full-year earnings of ($0.59) per share for the current year. For the next financial year, analysts expect that the company will report earnings of ($0.55) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Kintara Therapeutics.

Kintara Therapeutics (NASDAQ:KTRAGet Rating) last issued its quarterly earnings results on Friday, February 11th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.06.

Separately, HC Wainwright lowered their price target on shares of Kintara Therapeutics from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, January 20th.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Kintara Therapeutics by 77.3% during the 4th quarter. Geode Capital Management LLC now owns 517,966 shares of the company’s stock valued at $264,000 after purchasing an additional 225,902 shares during the period. Citadel Advisors LLC bought a new position in shares of Kintara Therapeutics during the fourth quarter valued at approximately $127,000. Renaissance Technologies LLC purchased a new stake in Kintara Therapeutics in the fourth quarter worth $104,000. Virtu Financial LLC boosted its holdings in Kintara Therapeutics by 371.4% in the fourth quarter. Virtu Financial LLC now owns 64,913 shares of the company’s stock valued at $33,000 after acquiring an additional 51,144 shares in the last quarter. Finally, Two Sigma Investments LP bought a new stake in Kintara Therapeutics in the third quarter valued at $47,000. 13.47% of the stock is currently owned by institutional investors.

Shares of Kintara Therapeutics stock traded down $0.01 during trading on Wednesday, reaching $0.28. The company’s stock had a trading volume of 14,515 shares, compared to its average volume of 987,740. Kintara Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.85. The firm’s 50-day moving average is $0.38 and its two-hundred day moving average is $0.57. The company has a market cap of $13.84 million, a price-to-earnings ratio of -0.40 and a beta of 1.64.

About Kintara Therapeutics (Get Rating)

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.

Recommended Stories

Get a free copy of the Zacks research report on Kintara Therapeutics (KTRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with's FREE daily email newsletter.